1. Academic Validation
  2. Pancreatic polypeptide inhibits somatostatin secretion

Pancreatic polypeptide inhibits somatostatin secretion

  • FEBS Lett. 2014 Aug 25;588(17):3233-9. doi: 10.1016/j.febslet.2014.07.005.
Wook Kim 1 Jennifer L Fiori 2 Yu-Kyong Shin 2 Eitan Okun 3 Jung Seok Kim 1 Peter R Rapp 4 Josephine M Egan 5
Affiliations

Affiliations

  • 1 Department of Molecular Science and Technology, Ajou University, Suwon 443-749, South Korea.
  • 2 Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • 3 The Mina and Everard Goodman Faculty of Life Sciences, The Leslie and Susan Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan 52900, Israel.
  • 4 Laboratory of Behavioral Neuroscience, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
  • 5 Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA. Electronic address: [email protected].
Abstract

Pancreatic polypeptide (PP) is a major agonist for neuropeptide Y4 receptors (NPY4R). While NPY4R has been identified in various tissues, the cells on which it is expressed and its function in those cells has not been clearly delineated. Here we report that NPY4R is present in all somatostatin-containing cells of tissues that we tested, including pancreatic islets, duodenum, hippocampus, and hypothalamus. Its agonism by PP decreases somatostatin secretion from human islets. Mouse embryonic hippocampal (mHippo E18) cells expressed NPY4Rs and their activation by PP consistently decreased somatostatin secretion. Furthermore, central injection of PP in mice induced c-Fos immunoreactivity in somatostatin-containing cells in the hippocampus compared with PBS-injected mice. In sum, our results identify PP as a pivotal modulator of somatostatin secretion.

Keywords

NPY4 receptor; Pancreatic polypeptide; Somatostatin secretion.

Figures
Products